With 1.84 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.91 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $7.02 whereas the lowest price it dropped to was $6.88. The 52-week range on BKD shows that it touched its highest point at $7.05 and its lowest point at $3.33 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BKD was up-trending over the past week, with a rise of 7.41%, but this was up by 5.61% over a month. Three-month performance surged to 22.54% while six-month performance rose 82.68%. The stock gained 65.32% in the past year, while it has gained 19.59% so far this year. A look at the trailing 12-month EPS for BKD yields -0.84 with Next year EPS estimates of -0.58. For the next quarter, that number is -0.17. This implies an EPS growth rate of 16.07% for this year and 17.02% for next year. EPS is expected to grow by 10.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 21.51%.
Float and Shares Shorts:
At present, 188.25 million BKD shares are outstanding with a float of 168.14 million shares on hand for trading. On 2024-04-15, short shares totaled 18.72 million, which was 987.9999999999999 higher than short shares on 1710460800. In addition to Ms. Lucinda M. Baier as the firm’s President, CEO & Director, Ms. Dawn L. Kussow serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 1.06699 of BKD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, BKD reported revenue of $754483000.0 and operating income of $6729000.0. The EBITDA in the recently reported quarter was $103844000.0 and diluted EPS was -$0.4.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BKD since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
